USPTO serial 88501012
Serial No. 88501012
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SABLE, ERIC
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 88501012?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma | ACTIVE | — |
| 009 | Downloadable software in the nature of a mobile application for providing information relating to the treatment of ophthalmic diseases and disorders | ACTIVE | — |
| 035 | Business administration of patient reimbursement programs; business administration of medication reimbursement programs and services; business administration of pharmacy reimbursement programs and services; doctor's appointment reminder services pertaining to patient visits to doctors, medical centers and specialists, namely, ophthalmologists | ACTIVE | — |
| 041 | Educational and training services, namely, conducting classes, seminars and workshops in the field of ophthalmic diseases and disorders; providing online non-downloadable publications in the nature of articles, books and journals in the field of ophthalmic diseases and disorders and the monitoring and management of said diseases and disorders | ACTIVE | — |
| 042 | Providing temporary use of a non-downloadable web application for processing patient information related to ophthalmology | ACTIVE | — |
| 044 | Providing medical information in the field of ophthalmic diseases and disorders; medical services, namely, assisting in the observation, monitoring, adherence and compliance of patients to medical treatments | ACTIVE | — |
| 045 | Organizing and conducting support groups in the field of ophthalmology; Social networking services in the field of ophthalmological diseases and disorders and the monitoring and management of said diseases and disorders provided via a website | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Novartis AG
- Other trademarks owned by Novartis AG
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 5, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 5, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 3, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 2, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 2, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 25, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 25, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 26, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 23, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 23, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 23, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 14, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 23, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 23, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 23, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 28, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 26, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 26, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 26, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 24, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 22, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 22, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 22, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 29, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 3, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 3, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 14, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 30, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jul 20, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 19, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 19, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 19, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 18, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 16, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 14, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 8, 2019 | NWAP | NEW APPLICATION ENTERED | — |